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Abstract  
BACKGROUND: According to the literature, performance status, stage-tumor dimension and nodal 
status, weight loss, were the most important prognostic factors for survival in patients with locally 
advanced non-small cell lung cancer.  
AIM: To evaluate the treatment results and the prognostic variables in our patients treated with 
sequential and concurrent chemoradiotherapy. 
MATERIAL AND METHODS: In the study 85 patients were randomly assigned to one of the two 
treatment arms. In the sequential arm, 45 patients had previously received sequential 
chemotherapy with 4 cycles of and etoposide followed by conformal radiotherapy (RT). In the 
second concurrent group, 40 patients received concomitant chemotherapy of cisplatine and 
etoposide and conformal RT, followed by two cycles of consolidation chemotherapy of carboplatine 
and etoposide. We described all phases of the conformal three dimensional (3-D) RT.  
RESULTS: From October 2005 to March 2008, 93 patients were enrolled. Eight patients were not 
eligible, seven had stage IV and one patient had pleural effusion. They were all initially considered 
to have stage IIIB disease.  The median survival was 13 months for the patients in the sequential 
arm and 19 months for those in the concurrent treatment arm. The differences were statistically 
significant (log-rank test p=0.0039). The disease-free survival was 9 months in the sequential arm 
and 16 months in the concurrent treatment group. The differences were statistically significant (log-
rank test p=0.0023). We found that the following prognostic factors significantly influenced the 
survival in lung cancer patients treated with conservative method: - age, p<0.05; - performant 
status, p<0.001; - weight loss, p<0.001; tumor dimension, p<0.05; and - nodal involvement, p<0.05. 
CONCLUSION: In our study, the dose-limiting toxicity, esophagitis was reduced by performing 
conformal radiotherapy. Conformal thoracic radiotherapy and new radiotherapy technics, such as 
respiratory gated radiotherapy, allow dose escalating and may probably improve survival and local 
control in lung cancer patients. 
 
 
 
 
 
Introduction 
 
Lung cancer remains a worldwide epidemic. 
Approximately 1.2 million people die from lung cancer 
each year. NSCLC represents >80% of all lung 
cancers. 60%-70% of the patients with NSCLC suffer 
stage III or IV disease. In the late 1980s, radiotherapy 
was the standard treatment for these patients [1]. 
Randomized trials and a 1995 overview subsequently 
showed that combination/combined chemoradio-
therapy was superior to radiotherapy alone [2]. Many 
chemotherapeutic agents active in NSCLC possess 
radiosensitizing properties, thereby improving the 
probability of local control. In addition, chemotherapy 
administered concurrently with thoracic radiation may 
act systemically and potentially eradicate distant 
micrometastases. Several studies showed the 
feasibility of the cisplatin-etoposide combination plus 
radiotherapy for patients with stage III disease [3].  
Successfully tailored therapy in lung cancer 
patients requires defining the prognostic factors. 
Prognostic factors are defined as characteristics of 
patients and stage, before starting the treatment. 
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Analyzing these characteristics provides the 
opportunity to select patients in different groups and 
choose the best treatment modality for the selected 
group. They are also important to evaluate the results 
of treatments and to compare the results of different 
clinical studies [4]. 
Primary end point of this study was to 
evaluate the treatment results and the prognostic 
variables in our patients treated with sequential and 
concurrent chemoradiotherapy. 
 
 
Material and Methods 
 
 One hundred and ten patients with NSCLC 
stage IIIA and IIIB were analyzed at the University 
Clinic of Radiotherapy and Oncology in Skopje in the 
period from October 2005 to March 2008. Only 85 
patients were eligible for this study, aged between 18 
and 70 years, had an Eastern Cooperative Oncology 
Group (ECOG) Score ≤ 1, and had ≤ 10 % weight loss 
in the period of 3 months before inclusion. They have 
previously untreated histological or cytological proven 
NSCLC, unrespectable stage IIIA-N2 disease, or 
stage IIIB disease without pleural effusion. Stage IIIB 
disease was assigned either by N3 (contralateral 
mediastinal or supraclavicular nodes) or by T4 from 
invasion of mediastinal structures. Following 
prognostic factors were evaluated: aged (18-43, 44-
55, 56-70); histological type (squamous, 
adenocarcinoma large cell carcinoma and unspecified 
type); performance status (PS) according to ECOG 
Score ≤ 1, weight loss in the period of 3 months 
before inclusion (< 5%, 5-10%); lymph nodes 
involvement and tumor dimension (5 cm, > 5 cm and 
unmeasurment because atelectasis, pneumonitis); 
symptoms duration before treatment (< 3 months, 3-6 
months, > 6 months); and hemoglobin level (<120 g/l, 
≥ 120 g/l).  
The following laboratory values were required: 
leucocytes ≥ 1.5x10³/l, platelets ≥ 100x10/l, AST and 
ALT ≤ 2 x the upper limit of the reference range. 
Ineligibility criteria were as follows: uncontrolled 
infection, or fever over 38ºC, unstable cardiovascular 
disease and previous malignancy. 
Before enrolment, the patients gave their full 
medical histories and underwent clinical examination 
with assessment of performance status (PS). In the 
sequential arm, responses were assessed 8 weeks 
after the end of radiotherapy. In the concurrent arm, 
responses were assessed 8 weeks after the end of 
the consolidation chemotherapy. Imaging studies x-
ray and/or computed tomography (CT) could be 
repeated at all times when clinically indicated. 
Complete and partial responses were based on 
RECIST criteria. Toxicity was graded according to 
RTOG/EORTC criteria. Follow-up visits were 
conducted every 2 months during the first year and, 
afterwards, every 3 months. Patients were randomly 
assigned to receive sequential or concurrent therapy. 
In the sequential arm, 45 patients received four cycles 
of chemotherapy. They were administered first, 
consisting of carboplatin (AUC x 6) on day 1 and 
etoposide on days 1-3, repeated every 3 weeks. The 
radiotherapy began 4 weeks after the fourth cycle of 
chemotherapy administration. Chemotherapy and 
radiotherapy began simultaneously in concurrent arm, 
including 40 patients. The radiotherapy schedule was 
identical to that in the sequential arm. The first cycle 
with cisplatin 30 mg/m² and etoposide 100mg/m² was 
administered on days 1 to 3 and the second 3-days 
cycle was administered the last 3 days of 
radiotherapy. After 4 weeks of concurrent 
chemoradiotherapy schedule, two cycles of 
consolidation chemotherapy began, consisting of 
carboplatine (AUC x 6) and etoposide 100 mg/m² on 
day 1 to 3. 
Conformal radiotherapy at both arms 
consisted of 60 Gy in 30 fractions of 2 Gy per fraction, 
for 5 days a week given over a period of 6 weeks. 
Treatment planning CT was required to define the 
gross tumor volume (GTV). Each patient was 
positioned in an immobilization device-wing board in 
the treatment position on a flat table. CT slices with 5 
mm thickness were obtained, starting from cricoid 
cartilage and extending inferiorly to the level of the L1 
vertebral body. The GTV, clinical target volume (CTV), 
planning target volume (PTV) and normal organs were 
outlined on all CT slices (Figure 1).  
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Figure 1: ECOG status and survival. 
 
The normal tissues that were contoured 
included both lungs (as the total lung volume), heart, 
spinal cord and esophagus.  The CTV included the 
entire GTV plus 0.7 cm and the PTV included CTV 
plus another 0.7 cm adding margin. PTV44 was 
treated with parallel-opposed anterior-posterior fields 
and PTV60 was treated with any combination of fields 
depends of spinal cord constrain (Figure 2).  
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Figure 2: Survival according to tumor dimension. 
 
If radiotherapy had to be delayed for more 
than 7 days, the patient was withdrawn from the 
study. Patients with evidence of progression at any 
time were removed from the study, but continued to 
be evaluated for survival and toxicity. Survival and 
interval to recurrence or progression were measured 
from the date of the first treatment session.     
 
 
Results 
 
From October 2005 to March 2008, 93 
patients were enrolled. Eight patients were not 
eligible, seven had stage IV and one patient had 
pleural effusion. All these were initially considered to 
have stage IIIB disease. The characteristics of 85 
patients are listed in Table 1.  
Table 1: The characteristics of 85 patients. 
  Patient characteristics 
Concurrent 
chemoradiotherapy arm 
Sequential 
chemoradiotherapy 
arm 
 p 
No of eligible pts                       40 45  
Age 
18-43 
44-55 
56-70 
 
 
20 
 
20 
 
1 
13 
32 
 
0.13 
Sex 
Male 
Female 
 
35 
5 
 
40 
5 
0.98 
Performance status 
0 
1 
 
26 
14 
 
23 
22 
0.19 
Weight loss 
<5% 
5-10% 
 
26 
14 
 
23 
22 
0.13 
Histology 
Squamous cell 
Adenocarcinoma 
Large cell 
Unspecified 
 
22 
10 
3 
5 
 
34 
6 
2 
3 
0.26 
N status 
 N1 
N2 
N3 
 
12 
25 
3 
 
15 
27 
3 
0.93 
Tumor ≤ 5 sm 
Tumor > 5 sm 
14 
27 
18 
20 
0.38 
Hemoglobin 
<120 g/l 
≥120 g/l 
 
11 
29 
 
19 
26 
0.15 
Duration of symptoms 
< 3 months 
3-6 months 
> 6 months 
 
2 
21 
17 
 
0 
23 
22 
0.29 
Survival was analyzed until July 2009, after a 
median follow-up of 3 years. The median survival was 
13 months in the sequential arm (95%CI 10.2-15.7), 
and 19 months in the concurrent treatment arm 
(95%CI 13.6-24.3). The differences were statistically 
significant (log-rank test p = 0.0039, Figure 3).  The 1-
year, 2-year and 3-year survival rates were 74%, 36% 
and 27% in the concurrent arm and 52%, 14% and 
7.1% in the sequential arm, respectively. Disease free 
survival for the concurrent arm was 16 months (95% 
CI 12.7-19.2), and for the sequential arm was 9 
months (95% CI 5.8- 12.16). The differences were 
statistically significant (log-rank test p = 0.0023 Figure 
4). 
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Figure 3: Overall survival according to the treatment. 
 
 One of the aims of this study was to evaluate 
the prognostic factors. The analysis was not 
performed according to the treatment modality: 
sequential or concurrent, because the two groups 
were homogeneous without significant differences 
between them.  
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Figure 4: Disease-free survival according to the treatment. 
 
 Most patients in our study were between 44-
55 and 56-70 years of age. The youngest patient was 
38 years old and the oldest was 70 years old. Average 
age was 58.2 years (SD ± 6.68 years). Patients aged 
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between 44 and 55 had median survival of 14 months 
(95% CI 10.15-17.84), significantly better than the 
patients between 56 and 70 years of age, with median 
survival time of 10 months (95% CI 4.3-15.6) (p<0.05). 
 As we expected, performance status, 
according to ECOG criteria, has important influence 
on survival. Overall survival for patients with ECOG 0 
was 19 months, significantly better than 10 months for 
patients with ECOG 1 status (p<0.001), (Figure 1).  
 Another prognostic factor influencing the 
survival was weight loss in the period of 3 months 
before inclusion. Median survival in patients group 
with weight loss under 5% was 16 months (95% CI 
12.2 months to 19.7 months) and was, in statistical 
terms, significantly better than 7 months (95% CI 5.5 
months to 11.3 months) in patients with weight loss 
between 5% and 10% (p<0.001).  
 Tumor dimension was also an important 
prognostic factor with statistical influence on survival 
(p<0.001). Patients with tumor dimension under 5 cm 
in size have median survival of 20 months (95% CI 
13.6-26.3), compared with survival of 13 months at 
patients with tumors dimension over 5 cm in size 
(95% CI 9.8 months to 16.1 months) and 9 months 
(95% CI 6.1 months to 13.8 months) at unmeasured 
tumors (Figure 2).  
 Lymph nodes involvements also have 
statistical influence on survival in lung cancer patients 
treating with chemoradiotherapy. Patients with N1 
lymph nodes involvement live the longest median of 
20 months (95% CI 11.1 months to 32.8 months), 
compared to 13 months (95% CI 9.6 months to 16.3 
months) at patients with N2 involvements and 7 
months (95% CI 5.8 -8.1) at those patients with N3 
involvement (p<0.001).  
 Another parameter we analyzed in this study 
was hemoglobin level in patients’ blood. Patients with 
hemoglobin level under 120 g/l had survival average 
of 9 months (95% CI 6.5 -11.4), and patients with 
hemoglobin level over 120 g/l had survival of 
approximately 17 months (95% CI 12.9-21.1). The 
differences between two groups of patients were high, 
but still not statistically significant (p=0.06), (Table 2). 
Table 2: Survival according to hemoglobin level. 
Hemoglobin 
level 
Average 
(months) 
12 
Months 
(%) 
24 
Months 
(%) 
36 
Months 
(%) 
Total 
<120 g/l 9 44% 14% 0% 30 (35%) 
≥120 g/l 17 72% 29% 16% 55 (65%) 
 p = 0.06  
 
85 (100%) 
 
 In our study histological type of lung tumors, 
gender and duration of symptoms, before starting the 
treatment, were prognostics factors without any 
significant influence on survival. 
 
Discussion 
 
Our study compared sequential and 
concurrent chemoradiation therapy in locally 
advanced NSCLC. We found more benefit of 
concurrent therapy than in the previously listed trials, 
in terms of overall and disease-free survival (19 vs 13; 
16 vs 9 months), and the difference was significant 
with log-rank test. When our study was designed, the 
cisplatin-etoposide combination was mostly used 
concurrently with radiotherapy. Consolidation 
chemotherapy with two cycles of carboplatin-
etoposide was administered in the concurrent arm to 
balance the dose of platinum based chemotherapy in 
the two arms. This consolidation chemotherapy 
administered after concurrent chemoradiotherapy 
seems promising in terms of survival, as shown in the 
Southwest Oncology Group (SWOG) S9504 and 
Locally Advanced Multimodality Protocol (LAMP) 
studies [5, 6]. In the SWOG S9504 study, 
consolidation docetaxel following concurrent 
chemoradiotherapy has shown median survival of 26 
months and median progression free survival of 16 
months. Our concurrent-consolidation arm showed 
similar results (OS 19 months and DFS 16 months). In 
our study, the local relapse rate was lower in the 
concurrent arm than in the sequential arm. In the 
RTOG 94-10 [7] study, local failure rates at 2 years 
were significantly lower in the concurrent arm. Thus, it 
seems that the superior survival observed with 
concurrent treatment is associated with better local 
control [8-10].  
Sealy at all [11] informed that elderly patients 
with inoperable lung cancer manifested local disease 
recurrence, while younger patient showed distant 
dissemination, proven in our study. According to the 
most authors, gender did not influence survival. 
According to the literature, number of female 
with lung cancer was increasing with decreasing ratio 
male/female. We did not confirm this in our study, 
because, in Macedonia, smoking among the female 
population was rarity [12].  
According to our study, histology type of lung 
cancer did not influence the survival, but same data 
from the literature confirm that squamous lung cancer 
patients live longer than those with adenocarcinoma 
[13].  
We have confirmed in our study that tumor 
dimension was an important factor influencing the 
survival. Perez informed that that there was only 
correlation between tumor dimension and local 
disease control without influence on the survival [14]. 
The most important prognostic factor 
according to the literature was the performance 
status. We also confirmed that the performance status 
before starting the treatment had statistically 
significant influence on the survival [15]. 
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In our study, median survival in patients’ 
group with weight loss under 5% was 16 months and 
was significantly better, in statistical terms, than 7 
months in patients’ group with weight loss between 5 
and 10%. Data from the literature confirmed our 
conclusion [16]. 
We highly recommend precisely defining the 
stage of disease and the prognostic factors in lung 
cancer patients and hoping that in better selected 
patient group the chance for giving best treatment will 
be higher.  
Given the high toxicity in the concurrent-
consolidation schedule, it should be reserved for 
patients younger than 70 years, having good 
performance status and minimal weight loss. In our 
study, the dose-limiting toxicity, esophagitis was 
reduced by performing conformal radiotherapy. 
Conformal thoracic radiotherapy and new 
radiotherapy techniques, such as respiratory gated 
radiotherapy, allow dose escalating and may probably 
improve survival and local control in lung cancer 
patients.  
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